blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3342770

EP3342770 - QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.02.2023
Database last updated on 28.05.2024
FormerThe patent has been granted
Status updated on  25.02.2022
FormerGrant of patent is intended
Status updated on  19.10.2021
FormerExamination is in progress
Status updated on  08.04.2020
FormerRequest for examination was made
Status updated on  04.01.2019
FormerThe application has been published
Status updated on  01.06.2018
Most recent event   Tooltip27.10.2023Lapse of the patent in a contracting state
New state(s): MC		published on 29.11.2023  [2023/48]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2018/27]
Inventor(s)01 / LI, David, Yunzhi
of AstraZeneca R&D China
Innovation Center China, 199 Liangjing Road
Zhangjiang Hi-Tech Park, Shanghai 201203 / CN
02 / WANG, Jiabing
of AstraZeneca R&D China
Innovation Center China, 199 Liangjing Road
Zhangjiang Hi-Tech Park, Shanghai 201203 / CN
03 / YANG, Zhenfan
of AstraZeneca R&D China
Innovation Center China, 199 Liangjing Road
Zhangjiang Hi-Tech Park, Shanghai 201203 / CN
04 / ZENG, Qinbei
of AstraZeneca R&D China
Innovation Center China, 199 Liangjing Road
Zhangjiang Hi-Tech Park, Shanghai 201203 / CN
05 / ZHANG, Xiaolin
of AstraZeneca R&D China
Innovation Center China, 199 Liangjing Road
Zhangjiang Hi-Tech Park, Shanghai 201203 / CN
 [2018/27]
Representative(s)Snaith, James Michael, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2018/27]
Application number, filing date17179729.305.03.2014
[2018/27]
Priority number, dateWO2013CN7225006.03.2013         Original published format: PCT/CN2013/072250
[2018/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3342770
Date:04.07.2018
Language:EN
[2018/27]
Type: B1 Patent specification 
No.:EP3342770
Date:30.03.2022
Language:EN
[2022/13]
Search report(s)(Supplementary) European search report - dispatched on:EP26.04.2018
ClassificationIPC:C07D403/12, A61K31/517, A61P35/00
[2018/27]
CPC:
A61K31/517 (EP,RU,US); A61K31/4184 (EP,US); A61K31/495 (RU);
A61K31/4985 (EP,US); A61K31/519 (EP,US); A61K39/3955 (US);
A61K45/06 (EP,US); A61P35/00 (EP); A61P35/02 (EP);
A61P35/04 (EP); C07D403/12 (EP,RU,US) (-)
C-Set:
A61K31/4184, A61K2300/00 (US,EP);
A61K31/4985, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/06]
Former [2018/27]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:CHINAZOLIN-INHIBITOREN ZUR AKTIVIERUNG MUTANTER FORMEN DES EPIDERMALEN WACHSTUMSFAKTOR-REZEPTORS[2018/27]
English:QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR[2018/27]
French:INHIBITEURS DE QUINAZOLINE POUR ACTIVER DES FORMES MUTANTES DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE[2018/27]
Examination procedure21.12.2018Examination requested  [2019/06]
21.12.2018Date on which the examining division has become responsible
18.04.2019Amendment by applicant (claims and/or description)
15.04.2020Despatch of a communication from the examining division (Time limit: M06)
17.11.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
27.01.2021Reply to a communication from the examining division
04.10.2021Cancellation of oral proceeding that was planned for 09.11.2021
20.10.2021Communication of intention to grant the patent
09.11.2021Date of oral proceedings (cancelled)
21.02.2022Fee for grant paid
21.02.2022Fee for publishing/printing paid
21.02.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP14710620.7  / EP2964638
Opposition(s)03.01.2023No opposition filed within time limit [2023/10]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
27.01.2021Request for further processing filed
27.01.2021Full payment received (date of receipt of payment)
Request granted
05.02.2021Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
18.04.2019Request for further processing filed
18.04.2019Full payment received (date of receipt of payment)
Request granted
07.05.2019Decision despatched
Fees paidRenewal fee
05.07.2017Renewal fee patent year 03
05.07.2017Renewal fee patent year 04
13.03.2018Renewal fee patent year 05
13.03.2019Renewal fee patent year 06
12.03.2020Renewal fee patent year 07
12.03.2021Renewal fee patent year 08
14.01.2022Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL30.03.2022
AT30.03.2022
CZ30.03.2022
DK30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
IT30.03.2022
LT30.03.2022
LV30.03.2022
MC30.03.2022
NL30.03.2022
PL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SI30.03.2022
SK30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
IS30.07.2022
PT01.08.2022
[2023/48]
Former [2023/35]AL30.03.2022
AT30.03.2022
CZ30.03.2022
DK30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
IT30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
PL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SI30.03.2022
SK30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
IS30.07.2022
PT01.08.2022
Former [2023/25]AL30.03.2022
AT30.03.2022
CZ30.03.2022
DK30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
PL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SI30.03.2022
SK30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
IS30.07.2022
PT01.08.2022
Former [2023/07]AL30.03.2022
AT30.03.2022
CZ30.03.2022
DK30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
PL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SK30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
IS30.07.2022
PT01.08.2022
Former [2023/01]AL30.03.2022
AT30.03.2022
CZ30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
PL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SK30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
IS30.07.2022
PT01.08.2022
Former [2022/51]AT30.03.2022
CZ30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
PL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SK30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
IS30.07.2022
PT01.08.2022
Former [2022/50]AT30.03.2022
CZ30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
PL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SK30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
PT01.08.2022
Former [2022/49]AT30.03.2022
CZ30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SK30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
PT01.08.2022
Former [2022/48]AT30.03.2022
CZ30.03.2022
EE30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
PT01.08.2022
Former [2022/47]AT30.03.2022
ES30.03.2022
FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
RO30.03.2022
RS30.03.2022
SE30.03.2022
SM30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
PT01.08.2022
Former [2022/44]FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
NL30.03.2022
RS30.03.2022
SE30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
Former [2022/39]FI30.03.2022
HR30.03.2022
LT30.03.2022
LV30.03.2022
RS30.03.2022
SE30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
Former [2022/36]HR30.03.2022
LT30.03.2022
LV30.03.2022
RS30.03.2022
SE30.03.2022
BG30.06.2022
NO30.06.2022
GR01.07.2022
Former [2022/35]HR30.03.2022
LT30.03.2022
RS30.03.2022
SE30.03.2022
BG30.06.2022
NO30.06.2022
Former [2022/33]LT30.03.2022
NO30.06.2022
Documents cited:Search[AD]US2008167328  (HUANG WENLIN [CN], et al) [AD] 1-16 * claims 1-19 *;
 [AD]US2008177068  (HUANG WENLIN [CN], et al) [AD] 1-16* claims 1-19 *;
 [A]  - RI-DONG LI ET AL, "Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 21, no. 12, doi:10.1016/J.BMCL.2011.04.096, ISSN 0960-894X, (20110421), pages 3637 - 3640, (20110428), XP028387817 [A] 1-16 * figures 1,4; compound 11l *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2011.04.096
by applicantWO9512673
 WO9521915
 US5457105
 WO9633980
 WO9730034
 WO9738994
 WO9942585
 WO0055141
 WO0121594
 WO0218351
 WO03082831
 US6682736
 WO2005012290
 WO2005026156
 WO2005028469
 WO2005028470
 WO2005094357
 WO2005097137
 WO2005097134
 WO2006121168
 WO2007076245
 BRPI0602275
 US2008167328
 US2008177068
 US7488802
 CN101367793
 US2009055944
 WO2009101611
 WO2009114335
 WO2010061208
 US2010203056
 CN101857618
 US2011123552
 WO2011079804
 US8008449
 US8168757
 WO2012145493
 US2013034559
 US2013280275
 US2013323249
    - New England Journal of Medicine, (20080000), vol. 358, pages 1160 - 74
    - Biochemical and Biophysical Research Communications, (20040000), vol. 319, pages 1 - 11
    - Science, (20040000), vol. 304, pages 1497 - 500
    - New England Journal of Medicine, (20040000), vol. 350, pages 2129 - 39
    - PAO et al., Proceedings of the National Academy of Sciences of the United States of America, (20040000), vol. 13, pages 306 - 11
    - KOSADA et al., Cancer Research, vol. 64, pages 8919 - 23
    - ZHOU CC et al., Journal of Clinical Oncology, (20110000), vol. 12, pages 735 - 42
    - MOK TS et al., New England Journal of Medicine, (20090000), vol. 361, pages 947 - 57
    - MCKILLOP D et al., Xenobiotica, (20040000), vol. 34, pages 983 - 1000
    - JACKMAN DM et al., Journal of Clinical Oncology, (20060000), vol. 24, pages 4517 - 20
    - GROMMES C et al., Neuro-Oncology, (20110000), vol. 13, pages 1364 - 9
    - GAVRILOVIC et al., Journal of Neurooncology, (20050000), vol. 75, pages 5 - 14
    - BARNHOLTZ-SLOAN JS et al., Journal of Clinical Oncology, (20040000), vol. 22, pages 2865 - 72
    - SCHOUTEN LJ et al., Cancer, (20020000), vol. 94, pages 2698 - 705
    - LE RHUN et al., Surg Neurol Int, (20130000), vol. 4, pages 265 - 88
    - MILLER VA et al., Lancet Oncology, (20120000), vol. 13, pages 528 - 38
    - RAMALINGAM SS et al., Journal of Clinical Oncology, (20120000), vol. 30, pages 3337 - 44
    - DI L et al., Journal of Medicinal Chemistry, (20130000), vol. 56, pages 2 - 12
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.